Why the study?
Prehospital P2Y12 receptor antagonist use was historically common in ACS despite limited evidence, but recent guidelines no longer recommend it following clinical trials showing no benefit and higher bleeding.
Does early prehospital administration of P2Y12 receptor antagonists improve outcomes in patients with acute coronary syndromes?
Does early prehospital administration of P2Y12 receptor antagonists improve outcomes in patients with acute coronary syndromes?
The review highlights that recent European and Russian guidelines no longer recommend prehospital administration of P2Y12 receptor antagonists in NSTE-ACS due to increased bleeding without clinical benefit.
Answers are grounded in this paper and cite their sources.
Supports deferring prehospital P2Y12 antagonists in NSTE-ACS; leaves open optimal timing in undifferentiated or high-risk ACS.
Antithrombotic therapy is a cornerstone of acute coronary syndromes treatment, preventing coronary artery thrombosis development and progression. Early administration of P2Y12 receptor antagonists to patients with acute coronary syndromes (ACS) at the prehospital stage is a common practice and has been supported by the European and Russian Societies of Cardiology guidelines for many years despite the lack of definite evidence for its benefit. Recent clinical trials and registers on ACS treatment have shown no benefit and higher prevalence of bleeding related to the early start of P2Y12 receptor antagonists in NSTE-ACS patients. The latest European and Russian Societies of Cardiology guidelines do not recommend prehospital administration of P2Y12 receptor antagonists. The article highlights the antithrombotic therapy in acute coronary syndromes setting, recent ESC guidelines and its possible implementation in common practice.
No takes yet. Share an insight, caveat, or question.
Shalnev et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: